Three coded series of patients, 50 in all, with acute deep venous leg thrombosis of at most 96 hours' duration were treated with streptokinase (Kabikinase(R), Kabi) or heparin by intravenous drip (Table I) followed by subcutaneous heparin (150 to 250 regression was not always accompanied by improvement of the phlebograms. Administration of streptokinase was regularly followed by a high blood fibrinolytic activity. The plasminogen fell to 1 to 4% and the fibrinogen to 64% of the initial value. No split products could be demonstrated 24 hours after the infusion. In several of the streptokinase-treated patients bleeding complications occurred after the infusion during the treatment with subcutaneous heparin.
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Our findings show that streptokinase is superior to heparin in the treatment of acute venous thrombosis LE I , and functional ascending phlebography 5 2 1 were also used in this study.
DOSES OF STREPTOKINASE AND HEPARIN GIVEN INTRAVENOUSLY IN THE THREE SERIES
Twenty-six patients with extensive thrombosis but whose symptoms were of less than three days' duration were allocated, by a random method, to one of three patients treated with streptokinase, one of seven treated with Arvin, and two of seven given heparin.
Streptokinase was shown to cause extensive dissolution of thrombi in all but two of the 12 patients studied, sometimes within 12 hours but in one patient not until after six days of continuous infusion.
Methods and aims of laboratory control were discussed (Kakkar et al, 1969) and the side effects of each treatment described. Two fatal cases of retroperitoneal haemorrhage occurred in the heparin-treated group. There was only one other case of severe bleeding, an increased menstrual flow in a patient receiving streptokinase, and this was easily controlled. Most of the patients given streptokinase, but not those in the other groups, developed a pyrexia sometimes with rigors. One patient suffered a serious allergic reaction after a small part of the loading dose of streptokinase had been given; this responded to an antihistamine and hydrocortisone and the infusion was continued with ultimately complete dissolution of the thrombus.
Full results of the trial will be reported elsewhere. 3 Minor recent pulmonary embol. In two such patients streptokinase infusion was followed by complete disappearance of the filling defects seen on the pulmonary arteriograms when these were repeated at two and three days respectively. Complications of treatment included bleeding from skin incisions, haematoma formation, haematuria, and vaginal bleeding.
The indications for streptokinase in treating pulmonary embolism are not yet clear. Encouraging results were obtained in acute massive pulmonary embolism and these patients were spared embolectomy. Nonetheless there will be patients in whom the delay in response associated with streptokinase therapy is unacceptable and in whom embolectomy may be life-saving. Little benefit was obtained in three patients with thromboembolism of longer duration but resolution of minor recent emboli was demonstrated within three days in two patients. There is an urgent need for a controlled trial of streptokinase and of heparin therapy in such patients. Newcastle-upon-Tyne) The use of thrombolytic agents in coronary thrombosis has been based on the experimental work of Ruegsegger, Nydick, Hutter, Freiman, Bang, Cliffton, and LaDue (1959) . They described the lysis by streptokinase of thrombi artificially produced in the coronary arteries of dogs and showed that this lytic agent also substantially modified the histological appearances of the infarcts which followed the thrombosis. The lytic treatment had, however, to be given within three hours. A few controlled clinical trials have been
